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Abstract
Background: Minimally invasive breast biopsy technology is now considered a standard of care
for the diagnostic evaluation of suspicious breast lesions. The aim of the current study was to
present a comprehensive evaluation of the 8-gauge vacuum-assisted Mammotome® system for
ultrasound-guided diagnostic biopsy and selective excision of breast lesions.
Methods:  A retrospective analysis was conducted of a series of 304 consecutive 8-gauge
Mammotome® procedures that were performed under ultrasound guidance by a single surgeon
from March 2004 to December 2006. Multiple variables, including patient demographics,
characteristics of the breast lesion (based on ultrasound and mammography), procedural and
histopathology variables, and interval follow-up variables (based on ultrasound and mammography),
were evaluated.
Results: Among 304 procedures, 235 (77%) were performed with the presumption of complete
excision of the ultrasound lesion during Mammotome® core acquisition, while 69 (23%) were
performed with only partial excision of the ultrasound lesion during Mammotome® core acquisition
(diagnostic tissue sampling only). 100% of all ultrasound lesions were accurately diagnosed,
demonstrating no apparent false-negative results among the 256 patients that were compliant with
follow-up at a median interval follow-up duration of 11 months (range 1 to 37). Likewise, 89% of
all appropriately selected ultrasound lesions were completely excised, as demonstrated on interval
follow-up ultrasound at a median time of 6 months (range, 3 to 16). There were no independent
predictors of successful complete excision of any given appropriately selected ultrasound lesion by
the ultrasound-guided 8-gauge Mammotome® biopsy technique.
Conclusion: The 8-gauge vacuum-assisted Mammotome® system is highly accurate for ultrasound-
guided diagnostic biopsy of suspicious breast lesions and is highly successful for complete excision
of appropriately selected presumed benign breast lesions. This particular technology should be
routinely offered to all appropriately selected patients that are evaluated by physicians involved in
breast-specific health care.
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Background
Minimally invasive breast biopsy technology is now con-
sidered a standard of care for the diagnostic evaluation of
suspicious breast lesions [1]. In this regard, an innovative
vacuum-assisted breast biopsy technology was first com-
mercially introduced in 1995 by Biopsys Medical, Inc. in
Irvine, California [2] and was later acquired in 1997 and
successfully marketed by Ethicon Endo-Surgery, Inc. in
Cincinnati, Ohio [3]. This technology, the Mammotome®
breast biopsy system (Ethicon Endo-Surgery, Inc., Cincin-
nati, Ohio), was first utilized in stereotactic (mammo-
graphically-guided) applications [4] and was soon
thereafter adapted for ultrasound-guided applications [5].
Since that time, multiple reports have been published
using this technology for ultrasound-guided applications
[6-33]. The majority of these reports have evaluated the
11-gauge Mammotome® breast biopsy device [6-12,15,17-
22,24-26,28-30]. To date, only eight reports evaluating
the 8-gauge Mammotome® breast biopsy device for ultra-
sound-guided applications have been published
[13,14,16,23,27,31-33], with all such reports comparing
the 8-gauge system to that of the 11-gauge system. How-
ever, no single report has comprehensively outlined the
results of a large number of consecutively conducted ultra-
sound-guided breast biopsies performed by a single oper-
ator and solely using the 8-gauge Mammotome® breast
biopsy system. In the current report, we present a compre-
hensive evaluation of the 8-gauge vacuum-assisted Mam-
motome®  breast biopsy system for ultrasound-guided
diagnostic biopsy and selective excision of 304 breast
lesions.
Methods
This study protocol was approved by the Clinical Scien-
tific Review Committee and by the Cancer Institutional
Review Board of the Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute and Comprehensive
Cancer Center of the Ohio State University.
From the prospectively maintained operative log of a sin-
gle surgeon (SPP), all patients who underwent either an
ultrasound-guided diagnostic breast biopsy or an
attempted ultrasound-guided excision of a breast lesion
using the vacuum-assisted Mammotome® breast biopsy
system were identified. Prior to March 2004, both the 11-
gauge Mammotome® device and the 8-gauge Mammo-
tome® device were utilized by the above surgeon. Starting
in March 2004, the 8-gauge Mammotome® device was
exclusively utilized. From March 2004 to December 2006,
304 consecutive procedures were performed by the above
surgeon under ultrasound guidance using the 8-gauge
Mammotome® breast biopsy system. This particular group
of 304 consecutive 8-gauge Mammotome® procedures was
utilized for the current study. As a point of reference, dur-
ing the same time period, an additional 311 breast lesions
were also biopsied by the same surgeon under ultrasound
guidance using an Achieve® automated, spring-loaded 14-
gauge core biopsy device (Cardinal Health, Inc., McGraw
Park, Illinois) or a Bard® MaxCore™ automated, spring-
loaded 14-gauge core biopsy device (C.R. Bard, Inc., Cov-
ington, Georgia). All these breast biopsy procedures were
performed at JamesCare in Dublin (Dublin, Ohio), our
comprehensive breast health services facility of the Arthur
G. James Cancer Hospital and Richard J. Solove Research
Institute and Comprehensive Cancer Center of the Ohio
State University.
All breast lesions evaluated by the 8-gauge Mammotome®
breast biopsy system were sonographically visible and
were classified as BI-RADS (American College of Radiol-
ogy Breast Imaging Reporting and Data System) category
3, 4, or 5.
All 8-gauge Mammotome® procedures were performed by
a single surgeon (SPP) in the ultrasonography suite at
JamesCare in Dublin with the patient positioned supine
on a Biopsys exam table (model 106-004, Biopsys Medi-
cal, Inc., Irvine, California). Freehand real-time ultra-
sound guidance was performed using high-resolution
linear array transducers. Initially, ultrasound guidance
was performed using a Philips HDI 5000 SonoCT system
(Philips Medical Systems Andover, Massachusetts), with a
variable frequency transducer L12-5 (range 4.75 to 10.0
MHz). Later on, ultrasound guidance was performed
using a Philips iU22 system (Philips Medical Systems
Andover, Massachusetts), with either a variable frequency
transducer L12-5 (range 4.75 to 10.0 MHz) or a variable
frequency transducer L17-5 (range 5.75 to 7.0 MHz).
Local anesthetic, consisting of 1% lidocaine plain (used
for the skin and superficial tissues, and ranging from 8 to
12 mL) and 1% lidocaine containing 1:100,000 mixture
of epinephrine (used for the deeper breast tissues sur-
round the ultrasound lesion, and ranging from 15 to 25
mL) was utilized. After local anesthetic was administered,
a 5 mm skin incision was made with a #11 blade and
through which the 8-gauge Mammotome®  device was
passed and positioned just beneath the sonographic
lesion using real-time ultrasound guidance. Then, multi-
ple 8-gauge Mammotome® cores were sequentially taken
under real-time ultrasound guidance. In cases in which an
attempt was made to completely excise the ultrasound
lesion during core acquisition, multiple cores were taken
under ultrasound guidance while sequentially rotating the
8-gauge Mammotome®  device over an array spanning
approximately 180 degrees. The number of Mammo-
tome® cores harvested and the surgeon's impression as to
whether the ultrasound lesion was only partially sampled
for diagnostic tissue sampling purposes only or whether
the ultrasound lesion appeared to be completely excised
was documented in the operative report. An attempt atWorld Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
Page 3 of 13
(page number not for citation purposes)
complete ultrasound lesion excision was assessed in real-
time by taking longitudinal and transverse ultrasound
images both during core acquisition and after the comple-
tion of core acquisition. After the completion of core
acquisition, the 8-gauge Mammotome®  device was
removed and a 14-gauge Cormark™ rigid microclip device
(Ethicon Endo-Surgery, Inc., Cincinnati, Ohio) was
inserted under ultrasound guidance through the same
breast parenchymal track for placement of a microclip
into the residual ultrasound lesion of a partial removed
lesion or into the biopsy cavity of a presumed completely
removed lesion. Thereafter, manual compression to the
breast was performed for approximately ten minutes to
assure adequate hemostasis. The 5 mm incision site was
then generally closed with Steri-Strip™ adhesive skin clo-
sures (3 M Health Care, St. Paul, Minnesota).
For all patients, the findings on pathologic evaluation of
the 8-gauge Mammotome® breast biopsy were first dis-
cussed by telephone with the patient at the soonest avail-
ability of those results. All patients with abnormal
findings on pathologic evaluation that warranted surgical
intervention were appropriately managed. All patients
with benign findings on pathologic evaluation were asked
to return to JamesCare in Dublin for interval follow-up
clinical examination and breast imaging (generally both
ultrasound and mammography) at approximately six
months after the initial 8-gauge Mammotome® procedure.
Some variability in timing of interval follow-up for
patients with benign pathology occurred secondary to
patient availability and patient compliance issues. Some
patients with benign pathology remained noncompliant
and had no interval follow-up, even after multiple
attempts to arrange interval follow-up for such patients.
The data collection of all variables for this study was
accomplished by way of retrospective review of the elec-
tronic medical records system of the Ohio State University
Medical Center. Multiple variables were assessed and eval-
uated, including patient demographics, characteristics of
the breast lesion (based on ultrasound and mammogra-
phy), procedural and histopathology variables for the 8-
gauge Mammotome® biopsy technique, and interval fol-
low-up variables (based on ultrasound and mammogra-
phy).
The three dimensions (length, width, and height) of each
ultrasound lesion were obtained from the official ultra-
sound report. The length, width, and height were then
arbitrarily assigned to the designation of dimension 1,
dimension 2, or dimension 3, based solely on their
descending order in size. The volume of the original ultra-
sound lesion and the volume of any residual ultrasound
lesion seen at interval follow-up were both calculated
using the formula of the volume of an ellipsoid [4/
3·π·length axis radius·width axis radius·height axis
radius], rather than using the formula of a cuboid
[length·width·height], since the three-dimensional
shape of any given ultrasound lesion generally better
approximated that of an ellipsoid rather than that of a
cuboid [34]. The three dimensions (length, width, and
height) of the 8-gauge Mammotome® cores harvested at
the time of each procedure were obtained from the official
pathology report. The estimated volume of the 8-gauge
Mammotome® cores harvested was calculated using the
formula of the volume of a cuboid rather than the formula
of the volume of an ellipsoid, since the 8-gauge Mammo-
tome® cores harvested were generally measured by simply
placing them side-by-side into a configuration resembling
a cuboid.
The software program SPSS 14.0 for Windows (SPSS, Inc.,
Chicago, Illinois) was used for all statistical analyses. For
univariate comparisons of categorical variables, either
Pearson chi-square test or Fisher exact test was utilized.
Continuous variables were expressed as median (range).
For univariate comparisons of continuous variables, one-
way analysis of variance (ANOVA) was utilized. All
reported univariate P-values were two-sided. All univari-
ate P-values determined to be 0.05 or less were considered
to be significant. Multivariate logistic regression analysis
was performed in appropriately selected situations on all
variables with a univariate P-value of 0.10 or less, in order
to assess for the determination of possible independent
predictors.
Results
Patient demographics and characteristics of the original
breast lesions seen on the pre-Mammotome® procedure
ultrasound are shown in Table 1. Of the 304 ultrasound-
guided 8-gauge Mammotome®  biopsy procedures per-
formed, 235 (77%) were performed with the presump-
tion that the ultrasound lesion had been completely
excised during Mammotome® core acquisition, while 69
(23%) were performed with only partial excision of the
ultrasound lesion during Mammotome® core acquisition
(diagnostic tissue sampling only). Patients in which the
ultrasound lesion appeared to be completely excised dur-
ing Mammotome®  core acquisition were generally
younger, had a predilection toward BI-RADS category 3
and 4 classification of the breast lesion, and had a signifi-
cantly smaller original breast lesion size (including all
three dimensions of the original ultrasound lesion and
the original ultrasound lesion volume) based on the pre-
Mammotome® procedure ultrasound findings. Whereas,
patients in which only diagnostic tissue sampling was
undertaken during Mammotome® core acquisition were
generally older, had a predilection toward BI-RADS cate-
gory 4 and 5 classification of the breast lesion, and had aWorld Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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Table 1: Patient demographics and characteristics of the original breast lesions seen on the pre-Mammotome® procedure ultrasound: 
For all cases (n = 304), for cases in which an attempt to completely excise the breast lesion was made (n = 235), and for cases in which 
only diagnostic tissue sampling of the breast lesion was undertaken (n = 69)
All cases
(n = 304)
Attempted lesion 
excision
(n = 235)
Only diagnostic lesion 
sampling
(n = 69)
P-value
Age
(years)
47
(18–87)
44
(18–87)
53
(22–84)
< 0.001
Gender 0.539
Female 301
(99%)
233
(99%)
68
(99%)
Male 3
(1%)
2
(1%)
1
(1%)
Breast 0.158
Right 136
(45%)
100
(43%)
36
(52%)
Left 168
(55%)
135
(57%)
33
(48%)
Palpable tumor 0.057
Yes 150
(49%)
109
(46%)
41
(59%)
No 154
(51%)
126
(54%)
28
(41%)
Lesion location 0.185
UOQ 160
(53%)
124
(53%)
36
(52%)
UIQ 63
(21%)
45
(19%)
18
(26%)
LOQ 50
(16%)
44
(19%)
6
(9%)
LIQ 24
(8%)
18
(8%)
6
(9%)
Subareolar 7
(2%)
4
(2%)
3
(4%)
BI-RADS classification of ultrasound < 0.001
Category 3 55
(18%)
49
(21%)
6
(9%)
Category 4 231
(76%)
179
(76%)
52
(75%)
Category 5 18
(6%)
7
(3%)
11
(16%)
Was the ultrasound lesion also visible on pre-procedural 
mammogram?
0.251
Yes 190
(63%)
141
(60%)
49
(71%)
No 58
(19%)
48
(20%)
10
(15%)
Pre-procedural mammogram not done 56
(18%)
46
(20%)
10
(15%)
Original ultrasound lesion measurements
Dimension 1 (cm) 1.14
(0.33–5.53)
1.10
(0.33–3.12)
1.24
(0.50–5.53)
0.004
Dimension 2 (cm) 0.99
(0.24–3.74)
0.95
(0.24–2.52)
1.01
(0.40–3.74)
0.013
Dimension 3 (cm) 0.66
(0.22–1.80)
0.62
(0.22–1.70)
0.87
(0.30–1.80)
< 0.001
Volume of lesion (cubic cm) 0.38
(0.01–9.64)
0.35
(0.01–4.36)
0.63
(0.04–9.64)
< 0.001
UOQ, upper outer quadrant; LOQ, lower outer quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; BI-RADS, breast imaging 
reporting and data systemWorld Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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significantly larger original breast lesion size based on the
pre-Mammotome® procedure ultrasound findings.
Procedural and histopathology variables for the ultra-
sound-guided 8-gauge Mammotome® biopsy procedures
are shown in Table 2. For those cases in which the ultra-
sound lesion appeared to be completely excised during
Mammotome® core acquisition, significantly more tissue
was removed (based on the estimated number of Mam-
motome® core removed, estimated volume of Mammo-
tome®  cores removed, and percentage of estimated
volume of Mammotome® cores removed as compared to
the volume of the original breast lesion calculated on the
pre-Mammotome® procedure ultrasound) and the final
histopathology more frequently rendered a benign diag-
nosis (predominately fibroadenomas). For those cases in
which only diagnostic tissue sampling was undertaken
during Mammotome® core acquisition, significantly less
tissue was removed and the final histopathology more fre-
quently rendered a malignant diagnosis (predominately
invasive breast carcinomas). The overall number of post-
procedural complications (which included hematoma
formation, skin ecchymosis, or both) and the severity of
such complications seen were not significantly different
between the two groups. No intraoperative surgical man-
agement of any post-procedural complications was ever
required. No post-procedural infectious complications
were encountered.
Interval follow-up variables are shown in Table 3. Of the
304 patients who underwent an ultrasound-guided 8-
gauge Mammotome®  biopsy procedure, 256 (84%)
patients were compliant and returned for interval follow-
up, while 48 (16%) were noncompliant and did not
returned for interval follow-up. The frequency of such
interval follow-up was identical both for those patients in
which the ultrasound lesion appeared to be completely
excised during Mammotome® core acquisition and for
those patients in which only diagnostic tissue sampling
was undertaken during Mammotome® core acquisition.
Interval follow-up breast imaging was performed in 189
(62%) patients at a median time of 6 months (range, 3 to
16). This included 188 (62%) patients who underwent
interval follow-up ultrasound and 179 (59%) patients
who underwent interval follow-up mammogram. Instead
of interval follow-up breast imaging, 64 (21%) of the
patients underwent some sort of subsequent excisional
breast procedure at a time shortly after their initial ultra-
sound-guided 8-gauge Mammotome® biopsy procedure.
This included 46 invasive breast carcinomas, 4 cases of
ductal carcinoma in situ, 2 intracystic papillary carcino-
mas, 1 subcutaneous basal cell carcinoma of the breast, 2
cases of epithelial atypia, 3 benign breast tumors requir-
ing complete excision, 4 benign breast findings that were
incidentally excised within the same excisional specimen
as a known breast carcinoma, and 2 cases in which a
benign finding was incidentally excised as part a planned
prophylactic mastectomy. Far fewer patients in the group
in which only diagnostic tissue sampling was undertaken
during Mammotome® core acquisition had interval fol-
low-up breast imaging since far more of those same
patients had a malignant breast lesion that required some
sort of subsequent excisional breast procedure. For those
patients with a breast malignancy, 39 of 53 (74%) under-
went subsequent successful breast conservation therapy,
while 14 of 53 (26%) ultimately required a mastectomy
(including 5 for multifocal/multicentric disease, 3 for a
failed attempt at breast conservation therapy, 3 for subar-
eolar tumor location, and 3 as patient choice).
As is shown in Table 3, of those patients who were com-
pliant and returned for interval follow-up ultrasound
imaging (n = 188), 154 (82%) had no residual ultrasound
lesion visible on the interval follow-up ultrasound. As
would be expected, significantly more patients in which
the ultrasound lesion appeared to be completely excised
during Mammotome® core acquisition had no residual
ultrasound lesion visible on the interval follow-up ultra-
sound (n = 151/170, 89%), as compared to patients in
which the procedure was performed for the purpose of
only diagnostic tissue sampling during Mammotome®
core acquisition (n = 3/18, 17%). Thus, complete ultra-
sound lesions removal was confirmed on interval follow-
up ultrasound in 89% of patients in which the ultrasound
lesion appeared to be completely excised during Mammo-
tome® core acquisition. Overall, 34 (18%) patients who
underwent an ultrasound-guided 8-gauge Mammotome®
biopsy procedure and who had interval follow-up ultra-
sound demonstrated a residual ultrasound lesion on the
interval follow-up ultrasound, consisting of 19 (11%) of
those in which an attempt was made to completely excise
the original ultrasound breast lesion and 15 (83%) of
those in which the procedure was performed for the pur-
pose of only diagnostic tissue sampling.
Residual ultrasound lesion characteristics seen on interval
follow-up ultrasound imaging are shown in Table 4. All
residual ultrasound lesion characteristics seen on interval
follow-up ultrasound imaging (including all three dimen-
sions of the residual ultrasound lesion, the residual ultra-
sound lesion volume, and the percentage of volume of the
residual ultrasound lesion as compared to the original
ultrasound lesion) were significantly less for those 19
cases in which an attempt was made to completely excise
the original ultrasound breast lesion as compared to those
15 cases in which only diagnostic tissue sampling was per-
formed.
In Table 3, the presence or absence of a residual mammo-
graphic lesion on interval follow-up imaging poorly cor-World Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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related with the presence or absence of a residual
ultrasound lesion on interval follow-up imaging. This was
best exemplified by the fact that within the group of
patients that underwent a pre-procedural mammogram
(which demonstrated a mammographic lesion) and had
both an interval follow-up ultrasound and interval fol-
low-up mammogram that while 7 of 8 (88%) patients
undergoing diagnostic tissue sampling only during Mam-
motome®  core acquisition had a residual ultrasound
lesion on interval follow-up, comparatively only 4 of 8
(50%) of the same such patients had a residual mammo-
graphic lesion on interval follow-up.
As is shown in Table 5, for cases in which an attempt was
made to completely excise the ultrasound breast lesion,
the ability to originally palpate the ultrasound breast
lesion prior to the 8-gauge Mammotome® biopsy proce-
dure did not significantly influence whether a residual
ultrasound lesion could be seen on interval follow-up
ultrasound imaging. However, and as would be intuitively
deducted, the median size of the original ultrasound
breast lesion (including all three dimensions of the lesion
and the lesion volume) significantly correlated with
whether a residual ultrasound lesion could be seen on
interval follow-up ultrasound imaging, with smaller such
original ultrasound breast lesions being seen in the group
having no residual ultrasound lesion seen on interval fol-
low-up ultrasound imaging and with larger such original
ultrasound breast lesions being seen in the group having
a residual ultrasound lesion seen on interval follow-up
ultrasound imaging. Despite this apparent significant size
correlation that was demonstrated on ANOVA, multivari-
ate analysis using logistic regression failed to show that
any single original ultrasound breast lesion size parameter
could independently predict ones ability to know whether
a residual ultrasound lesion would be seen on interval fol-
low-up ultrasound imaging.
To date, the median duration of interval follow-up for
those 256 patients who were compliant and who returned
for interval follow-up has been 11 months (range, 1 to 37)
(Table 3). Of those 189 patients who have had interval
follow-up imaging, only 4 (2%) patients have developed
a subsequent clinical or breast imaging finding within the
same location of the breast as where the original ultra-
sound-guided 8-gauge Mammotome®  biopsy was per-
formed that has subsequently required an additional
breast biopsy procedure. These have included three repeat
ultrasound-guided 8-gauge Mammotome® biopsy proce-
dures (at 9, 12, and 30 months after the original Mammo-
Table 2: Procedural and histopathology variables for the ultrasound-guided 8-gauge Mammotome® biopsy technique: For all cases (n = 
304), for cases in which an attempt to completely excise the breast lesion was made (n = 235), and for cases in which only diagnostic 
tissue sampling of the breast lesion was undertaken (n = 69)
All cases
(n = 304)
Attempted lesion 
excision
(n = 235)
Only diagnostic lesion 
sampling
(n = 69)
P-value
Estimated number of Mammotome® cores removed 8
(2–38)
9
(3–38)
6
(2–17)
< 0.001
Estimated volume of Mammotome® cores removed (cubic cm) 2.18
(0.26–37.13)
2.50
(0.60–37.13)
1.38
(0.26–4.38)
< 0.001
Percentage of estimated volume of Mammotome® cores removed as compared 
to volume of original ultrasound lesion
615%
(9%–18,086%)
730%
(113%–18,086%)
222%
(9%–2263%)
< 0.001
Lesion histopathology < 0.001
Fibroadenoma 126
(41%)
112
(48%)
14
(20%)
Other benign findings 107
(35%)
88
(37%)
19
(28%)
Benign tumors 10
(3%)
7
(3%)
3
(4%)
Invasive breast cancer 47
(16%)
20
(9%)
27
(39%)
DCIS 4
(1%)
2
(1%)
2
(3%)
ICPC 2
(1%)
1
(< 0.5%)
1
(1%)
Lymphoma 3
(1%)
1
(< 0.5%)
2
(3%)
SQBCC 1
(< 0.5%)
0
(0%)
1
(1%)
Epithelial atypia 4
(1%)
4
(2%)
0
(0%)
Post-procedural complications (hematoma formation, skin ecchymosis, or both) 24
(8%)
20
(9%)
4
(6%)
0.462
DCIS, ductal carcinoma in situ; ICPC, intracystic papillary carcinoma; SQBCC, subcutaneous basal cell carcinomaWorld Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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tome® biopsy procedure) and one excisional biopsy (at 5
months after the original Mammotome® biopsy proce-
dure). All four such repeat breast biopsy procedures sim-
ply showed benign findings that were consistent with the
results of their previous original Mammotome® biopsy
findings. Therefore, to date, there have been no instances
within the group of 256 patients that were compliant with
interval follow-up in which the histopathology results of
the original ultrasound-guided 8-gauge Mammotome®
biopsy have changed (i.e, there have been no false-nega-
tive results).
Discussion
Within the last 15 years, the diagnostic evaluation of sus-
picious breast lesions has been significantly impacted
upon by the development of innovative minimally inva-
sive breast biopsy technologies. Such practices have been
rapidly adopted by those physicians involved in breast-
Table 3: Interval follow-up variables: For all cases (n = 304), for cases in which an attempt to completely excise the breast lesion was 
made (n = 235), and for cases in which only diagnostic tissue sampling of the breast lesion was undertaken (n = 69)
All cases
(n = 304)
Attempted 
lesion 
excision
(n = 235)
Only diagnostic 
lesion sampling
(n = 69)
P-value
Was any IFU done by patient? 0.678
Yes 256
(84%)
199
(85%)
57
(83%)
No 48
(16%)
36
(15%)
12
(17%)
Was IFU imaging performed? < 0.001
Yes 189
(62%)
170
(72%)
19
(28%)
No 51
(17%)
38
(16%)
13
(19%)
Instead had subsequent excisional breast procedure performed 64
(21%)
27
(12%)
37
(54%)
Median time to IFU imaging (months) for those (n = 189) undergoing IFU imaging 6
(3–16)
6
(3–16)
6
(3–8)
0.110
Was IFU ultrasound performed? < 0.001
Yes 188
(62%)
170
(72%)
18
(26%)
No 52
(17%)
38
(16%)
14
(20%)
Instead had subsequent excisional breast procedure performed 64
(21%)
27
(12%)
37
(54%)
Was a residual ultrasound lesion visible for those undergoing IFU ultrasound (n = 188)? < 0.001
Yes 34
(18%)
19
(11%)
15
(83%)
No 154
(82%)
151
(89%)
3
(17%)
Was IFU mammogram performed? < 0.001
Yes 179
(59%)
162
(69%)
17
(25%)
No 61
(20%)
46
(20%)
15
(22%)
Instead had subsequent excisional breast procedure done 64
(21%)
27
(12%)
37
(54%)
Was a residual mammographic lesion visible for those undergoing IFU mammogram (n = 179)? 0.001
Yes 11
(6%)
6
(4%)
5
(29%)
No 168
(94%)
156
(96%)
12
(71%)
For those undergoing a pre-procedural mammogram (which demonstrated a mammographic lesion) and who 
had both an IFU ultrasound and an IFU mammogram, was a residual ultrasound lesion visible on IFU ultrasound 
(n = 110)?
< 0.001
Yes 21
(19%)
14
(14%)
7
(88%)
No 89
(81%)
88
(86%)
1
(12%)
For those undergoing a pre-procedural mammogram (which demonstrated a mammographic lesion) and who 
had both an IFU ultrasound and an IFU mammogram, was a residual mammographic lesion visible on IFU 
mammogram (n = 110)?
0.001
Yes 9
(8%)
5
(5%)
4
(50%)
No 101
(92%)
97
(95%)
4
(50%)
Median duration of IFU (months) for those (n = 256) undergoing IFU 11
(1–37)
9
(2–37)
13
(1–30)
0.146
IFU, Interval follow-upWorld Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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specific health care and are now routinely considered a
standard of care [1]. To date, only eight published reports
(Table 6) can be found in the literature
[13,14,16,23,27,31-33] that have formally evaluated the
8-gauge vacuum-assisted Mammotome®  breast biopsy
device for ultrasound-guided applications, with all such
reports comparing the 8-gauge system to that of the 11-
gauge system. However, no single report has comprehen-
sively detailed the results of a large number of consecu-
tively conducted ultrasound-guided breast biopsies
performed by a single operator and solely using the 8-
gauge Mammotome® breast biopsy system. In that specific
regard, the current study represents a comprehensive eval-
uation of the 8-gauge vacuum-assisted Mammotome® sys-
tem for ultrasound-guided diagnostic biopsy and selective
excision of breast lesions.
In the current study, 100% of all ultrasound lesions were
accurately diagnosed by the ultrasound-guided 8-gauge
Mammotome®  biopsy technique, demonstrating no
apparent false-negative results among the 256 patients
that were compliant with follow-up at a current median
interval follow-up duration of 11 months (range 1 to 37).
In this regard, since over 50% of the invasive breast can-
cers diagnosed in the present series were less than one cen-
timeter in size, it is very apparent that the ultrasound-
guided 8-gauge Mammotome® biopsy technique is highly
advantageous for allowing generous and representative
tissue sampling and for high accuracy of correctly diag-
nosing suspicious small subcentimeter breast lesions. In a
similar regard, the ultrasound-guided 8-gauge Mammo-
tome® biopsy device may potentially minimize the risk of
histopathologic underestimation and false negative
results [25] that could potentially be associated with the
use of an automated, spring-loaded 14-gauge core biopsy
device. Such an event could theoretically occur in a similar
group of suspicious small subcentimeter breast lesions
secondary to positional overshooting or undershooting of
the automated, spring-loaded core acquisition chamber
while firing the 14-gauge core biopsy device.
In the current study, 89% of all appropriately selected
ultrasound lesions were completely excised by the ultra-
sound-guided 8-gauge Mammotome® biopsy technique,
as demonstrated on interval follow-up ultrasound at a
median time of 6 months (range, 3 to 16). This figure of a
nearly 90% success of complete excision on ultrasound-
guided 8-gauge Mammotome® biopsy exceeds the 73%
success of complete excision previously reported by Fine
et al [16]. The greater success of excision in the current
series is most likely attributed to several factors, including
the larger mean ultrasound lesion size reported by Fine et
al [16] and the exclusive use of the 8-gauge Mammotome®
device in the current series versus the use of both 8-gauge
and 11-gauge Mammotome® devices in the Fine et al series
[16]. Likewise, the ultrasound-guided 8-gauge Mammo-
tome® biopsy technique allows for on-going, real-time,
ultrasound-guided "tailoring" of the excision cavity of any
given presumed benign lesion that the operator is
attempting to completely excise at the time of the Mam-
motome® procedure. This is itself a potential advantage
over that of any percutaneous en bloc excision technique,
since such percutaneous en bloc excision techniques gen-
erally allow for only a one-time attempt at tissue acquisi-
tion and can theoretically require an additional diagnostic
procedure for complete excision any given presumed
benign lesion if positioning variation results in altered
coordinates of the region of initial en bloc tissue acquisi-
tion.
Therefore, when a breast lesion is sonographically visible,
it is our opinion that the 8-gauge Mammotome® system is
the desired and optimal method both for accurate diagno-
sis of any given suspicious ultrasound lesion and for com-
Table 4: Residual ultrasound lesion characteristics seen on interval follow-up ultrasound imaging (n = 188): For all cases (n = 34), for 
cases in which an attempt to completely excise the breast lesion was made (n = 19), and for cases in which only diagnostic tissue 
sampling of the breast lesion was undertaken (n = 15)
All cases
(n = 34)
Attempted lesion excision
(n = 19)
Only diagnostic lesion sampling
(n = 15)
P-value
Residual ultrasound lesion measurements
Dimension 1 (cm) 0.95
(0.32–2.50)
0.79
(0.46–1.70)
1.37
(0.32–2.50)
0.003
Dimension 2 (cm) 0.74
(0.29–2.03)
0.70
(0.42–1.50)
1.02
(0.29–2.03)
0.022
Dimension 3 (cm) 0.53
(0.26–1.50)
0.44
(0.26–0.81)
0.86
(0.29–1.50)
< 0.001
Volume of lesion (cubic cm) 0.18
(0.01–3.93)
0.13
(0.03–1.07)
0.65
(0.01–3.93)
0.006
Percentage of volume of residual ultrasound lesionas 
compared to volume of original ultrasound lesion
33%
(3%–366%)
22%
(3%–78%)
84%
(12%–366%)
0.002World Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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plete removal of appropriately selected presumed benign
ultrasound lesions. In this regard, and as emphasized by
Sebag et al [31], the 8-gauge Mammotome® system allows
for more rapid and larger volume tissue acquisition,
resulting in more representative tissue sampling in cases
of diagnostic breast biopsy and need for removal of fewer
total Mammotome® cores in cases of attempted complete
ultrasound lesion excision. Furthermore, as do all sur-
geons, we strongly advocate the adherence to sound onco-
logic principles for the complete surgical excision of
malignant breast lesions.
Since multivariate analysis using logistic regression failed
to show that any single original ultrasound breast lesion
parameter could independently predict the ability to
know whether a residual ultrasound breast lesion would
be seen on interval follow-up ultrasound imaging, then
one can not inexplicitly recommend a particular breast
lesion size threshold below which any given ultrasound
breast lesion can be successfully and completely excised
by the ultrasound-guided 8-gauge Mammotome® biopsy
technique. Despite this lack of any exact evidence to allow
one to set a finite size criteria for the successful complete
excision of appropriately selected ultrasound breast
lesions by the ultrasound-guided 8-gauge Mammotome®
biopsy technique, the present authors arbitrarily recom-
mend limiting any attempts at complete excision to that
of such breast lesions which approximate a prolate ellip-
soid (i.e., cigar-shaped) or a scalene ellipsoid (i.e., three
unequal dimensions) and to that of such breast lesions
that have a maximum lesion length of 2.5 cm and maxi-
mum lesion width of 1.5 cm. In contrast, no upper limit
for the maximum lesion height seems necessary when the
attempted ultrasound-guided 8-gauge Mammotome® exci-
sion procedure is performed by appropriate placement of
the Mammotome® device immediately beneath the ultra-
sound lesion. However, the most difficult breast lesions to
excise are those breast lesions that approximate an oblate
ellipsoid (i.e., disk-shaped) in which the largest two
nearly identical dimensions exceeds the 2.5 cm maximum
size limit or those breast lesions that approximate a per-
fect sphere in which the diameter exceeds the 2.5 cm max-
imum size limit. These above recommendations are
partially based on the experience of the present surgeon
(SPP) in the currently reported series, as well as are based
on the actual length of the tissue collection chamber (23
mm) and the actual inner diameter of the cutter blade (3.9
mm) for the 8-gauge Mammotome® biopsy device [35].
A major shortcoming of two of the other previously
reported ultrasound-guided 8-gauge Mammotome®
biopsy studies (Table 6) has been their reliance solely
upon interval follow-up mammography or upon interval
follow-up clinical examination to assess the breast for the
success of attempted lesion excision and their apparent
lack of the use of interval follow-up ultrasound [14,32]. In
the study by Johnson et al [14], they used only mammog-
raphy at the time of six-month interval follow-up. They
reported that there were no cases in which a documented
abnormal pre-procedural mammogram and subsequent
six-month mammogram demonstrated a retained lesion.
In the current study, the analogous observation seems
quite different as compared to Johnson et al [14]. As is
clearly shown in Table 3, for all patients with a pre-proce-
dural mammographic abnormality that underwent only
diagnostic tissue sampling during Mammotome®  core
acquisition, while 88% had a residual ultrasound lesion
on interval follow-up ultrasound, only 50% had a residual
mammographic lesion on interval follow-up mammogra-
phy. This clearly demonstrates that the presence or
absence of a residual mammographic lesion at the time of
interval follow-up poorly correlates to the presence or
Table 5: Variables influencing whether a residual ultrasound lesion is seen on interval follow-up ultrasound imaging for cases in which 
an attempt was originally made to completely excise the breast lesion and in which interval follow-up ultrasound imaging was obtained 
(n = 170)
All cases
(n = 170)
No residual ultrasound lesion seen
(n = 151)
Residual ultrasound lesion seen
(n = 19)
P-value
Was the original breast lesion palpable 0.242
Yes 77
(45%)
66
(44%)
11
(58%)
No 93
(55%)
85
(56%)
8
(42%)
Original ultrasound lesion measurements
Dimension 1 (cm) 1.13
(0.37–3.12)
1.10
(0.37–2.48)
1.44
(0.90–3.12)
< 0.001
Dimension 2 (cm) 0.98
(0.24–2.52)
0.93
(0.24–1.96)
1.32
(0.69–2.52)
< 0.001
Dimension 3 (cm) 0.63
(0.22–1.50)
0.60
(0.22–1.50)
0.85
(0.53–1.17)
0.007
Volume of lesion (cubic cm) 0.35
(0.01–4.36)
0.33
(0.01–3.48)
0.83
(0.23–4.36)
< 0.001World Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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absence of a corresponding residual ultrasound lesion.
Similarly, in the study by Vargas et al [32], no specific
interval follow-up imaging was reported and only interval
follow-up clinical examination was discussed. For similar
reasons, and as is reported in the current study, since less
than one-half of our ultrasound lesions that were
attempted to be excised at the time of the ultrasound-
guided 8-gauge Mammotome® biopsy were originally pal-
pable, then interval follow-up clinical examination alone
would seem to be a poor predictor of the success of
attempted lesion excision. In this regard, we highly rec-
ommend interval follow-up ultrasound surveillance of
the area of the previous ultrasound-guided 8-gauge Mam-
motome® biopsy at approximately six months after such a
biopsy, as well as highly recommend consideration of
placement of a microclip into the original biopsy site at
the time of the previous ultrasound-guided 8-gauge Mam-
motome® biopsy as a mechanism for aiding in the ongo-
ing mammographic surveillance and/or future
mammographic surveillance of such patients at an appro-
priately selected age. The importance for interval follow-
up ultrasound surveillance is clearly demonstrated in the
present series, and has been previously recognized by the
authors of several of the other ultrasound-guided 8-gauge
Mammotome® biopsy papers [13,16,23,31].
Lastly, the importance of placement of a microclip into
the biopsy site at the time of the original Mammotome®
biopsy procedure goes far beyond its potential usefulness
for ongoing and/or future mammographic surveillance
and clearly extends into the realm of its usefulness when
one is faced with the mandatory need for subsequent
imaged-guided excision to an area demonstrating malig-
nancy that was previously either partially excised or com-
pletely excised during the original Mammotome® biopsy
procedure. In such situations, the previous placement of a
microclip into the biopsy site at the time of the original
Mammotome® biopsy procedure allows for potential flex-
ibility for subsequent image-guided excision, especially
when a persistent ultrasound lesion is not well visualized
on post-Mammotome® biopsy ultrasound imaging. Some
have argued against microclip placement during ultra-
sound-guided Mammotome®  biopsy secondary to the
concept of hematoma-directed ultrasound-guided exci-
sion [36,37]. While this technique has proven usefulness,
its major drawback is the time-dependent limitation of
this technique secondary to the gradual reabsorption of
the hematoma [37]. Therefore, microclip placement into
the biopsy site at the time of the original Mammotome®
biopsy procedure remains critical even for those that
advocate hematoma-directed ultrasound-guided excision
Table 6: All studies reporting experience with the ultrasound-guided 8-gauge vacuum-assisted Mammotome® biopsy technique
Authors Year Total 
number of 
procedures
8-Gauge 11-Gauge Performed by Stated method of interval follow-up (IFU)
Fine et al. [13] 2002 124 75 49 ≥ 5 physicians ultrasound and clinical exam at 6 months
Johnson et al. [14] 2002 101 not specified not specified not specified mammography at 6 months
Fine et al. [16 ] 2003 216 127 89 ≥ 5 physicians ultrasound and clinical exam at 6 months
Carpentier et al. [23] 2005 42 24 18 2 physicians ultrasound at 8 weeks, 6 months, and 12 months
Grady et al. [27] 2005 542 189# 353# 2 physicians surgical excision in 47 of 52 patients evaluated for 
atypia
Sebag et al. [31] 2006 650 230* 420* 3 centers ultrasound, mammography, and clinical exam at 6 and 
12 months
Vargos et al. [32] 2006 210 169 41 not specified clinical exam at time not specified
Xiao et al. [33] 2006 174 104§ 70§ 2 physicians not specified
Povoski 2007 304 304 0 1 physician ultrasound and mammography at a median IFU of 6 
months
IFU, Interval follow-up
# Via a personal e-mail communication with Dr. Ian Grady (Redding, California) from April 23, 2007, it was estimated and verified by Dr. Grady that 
approximately 50% (approximately 189) of the 378 cases performed after July 2002 where done by the ultrasound-guided 8-gauge Mammotome® 
biopsy approach and approximately 50% (approximately 189) of the 378 cases performed after July 2002 where done by the ultrasound-guided 11-
gauge Mammotome® biopsy approach. Therefore, including the 164 cases that were done by the ultrasound-guided 11-gauge Mammotome® biopsy 
approach before July 2002, it was estimated that overall a total of approximately 353 ultrasound-guided 11-gauge Mammotome® biopsy procedures 
were performed and approximately 189 ultrasound-guided 8-gauge Mammotome® biopsy procedures were performed.
* Via a personal e-mail communication with Dr. Philippe Sebag (Lyon, France) from January 23, 2007, it was estimated and verified by Dr. Sebag that 
approximately 35% (approximately 230) of the 650 cases performed where done by the ultrasound-guided 8-gauge Mammotome® biopsy approach 
and approximately 65% (approximately 420) of the 650 cases performed were done by the ultrasound-guided 11-gauge Mammotome® biopsy 
approach.
§ Via a personal e-mail communication with Dr. Li Xiao (Changsha, China) from May 16, 2007, it was estimated and verified by Dr. Xiao that 
approximately 60% (approximately 104) of the 174 cases performed where done by the ultrasound-guided 8-gauge Mammotome® biopsy approach 
and approximately 40% (approximately 70) of the 174 cases performed were done by the ultrasound-guided 11-gauge Mammotome® biopsy 
approach.World Journal of Surgical Oncology 2007, 5:83 http://www.wjso.com/content/5/1/83
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since image-guided excision of the site of the original
tumor can still be directed toward localization of the
microclip in cases in which rapid hematoma resorption
has taken place. Along similar lines, microclip placement
into the biopsy site at the time of the original Mammo-
tome® biopsy procedure can be critical in those instances
in which preoperative neoadjuvant chemotherapy is
being considered, since a 100% pathologic response from
preoperative neoadjuvant chemotherapy may result in
complete resolution of any detectable mammographic or
ultrasound lesion at the site of the original tumor [38-40].
Once again, in this situation, image-guided excision of the
site of the original tumor can still be directed toward
localization of the microclip.
Conclusion
The 8-gauge vacuum-assisted Mammotome®  system is
highly accurate for ultrasound-guided diagnostic biopsy
of suspicious breast lesions and is highly successful for
ultrasound-guided complete removal of appropriately
selected presumed benign breast lesions. This particular
technology is a very viable and appropriate alternative to
smaller-gauged, automated, spring-loaded core biopsy
and to diagnostic open surgical breast biopsy for maxi-
mizing the accuracy of and for minimizing the invasive-
ness of any given diagnostic breast biopsy procedure. In
this regard, we believe that the 8-gauge vacuum-assisted
Mammotome® biopsy system should be routinely offered
to all appropriately selected patients that are evaluated by
physicians involved in breast-specific health care.
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